Atrial and Congescor


Atrial Symptoms and Causes

An arrhythmia is a problem with the speed or rhythm of the heartbeat. Atrial fibrillation (AF) is the most common type of arrhythmia. The cause is a disorder in the heart's electrical system.

Often, people who have AF may not even feel symptoms. But you may feel

  • Palpitations -- an abnormal rapid heartbeat
  • Shortness of breath
  • Weakness or difficulty exercising
  • Chest pain
  • Dizziness or fainting
  • Fatigue
  • Confusion

AF can lead to an increased risk of stroke. In many patients, it can also cause chest pain, heart attack, or heart failure.

Doctors diagnose AF using family and medical history, a physical exam, and a test called an electrocardiogram (EKG), which looks at the electrical waves your heart makes. Treatments include medicines and procedures to restore normal rhythm.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for atrial

atrial treatment research studies

Congescor clinical trials, surveys and public health registries

Find Drug Side Effect reports

Congescor Side Effects

Thrombocytopenia (4)
Fall (3)
Renal Failure Acute (3)
Erythema Multiforme (3)
Bradycardia (2)
Skin Toxicity (2)
Dermatitis (2)
Dehydration (2)
Leukopenia (2)
International Normalised Ratio Increased (2)
Urticaria (2)
Disorientation (2)
Erythema (1)
Face Injury (1)
Death (1)
Dysplasia (1)
Cardiac Arrest (1)
Facial Bones Fracture (1)
Viral Infection (1)
Bundle Branch Block Left (1)
Pruritus (1)
Prothrombin Time Prolonged (1)
Periorbital Haematoma (1)
Overdose (1)
Subcutaneous Haematoma (1)
Toxic Skin Eruption (1)
Hypocoagulable State (1)
Myelodysplastic Syndrome (1)
Head Injury (1)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews

Are bouts of deprsession relevant to Congescor tablets

Canbendrofluazide 2.5mg give me a cough

Had bouts of diharea the first week this is unusual doc increased dose was on half amount befor

Had bouts of dihareia normally once a day i am 78 blood presure is a little high

I am 48 and i have Atriel Fibrillation and am on Congescor and Warfarin whilst awaiting a 'Cardioversion'. i am desperately trying to lose weight, is Congescor blocking my weight loss or is it just my age?

I am 86 and have atrial fibrillation and congestive heart failure. On 8/12/11, I was given Congescor/hemifurmurate by the chemist instead of my normal Bisoprolol. Instructions did say that I may feel ill for a few days . Within 3 days I developed di

I am in atrial fib and I am waiting for ablation which should be in next two weeks. Of course, I am experiencing shortness of breath and fatique. But I also have a lot mucous which I have to expell early in the morning. Along with this , I

I am suffering from frequent severe headaches since starting Congescor. Has anyone else experienced this as a side effect?

I had atrial fib some months ago,was in the emegency room in resus,Metoprolol was used to resus me at that time---i have had lots of supvetricular-slow since but Metoprolol will NEVER be a choice for me,iv GOT to get my BP down but HOW?as it WONT be

I have just been prescribed Congescor and Ramipril after a triple heart bypass back in April. Having read the Info Sheet I was suprised to read that once on it I have to see my Doctor and be weaned off it. Has any one else been prescribed similar 9 m

Can Trileptal cause atrial fibralattion

Can Trileptal cause Atrial Fibrallation?

After a catheter ablation this past Augustfor atrial fib. my doctor prescribed Pradax. and after taking it for a month or 2 I began having nausea and stomach discomfort. It has escalated to much more severs pain and burning in my stomach&am

Atrial flutter, A fib, bundle branch block

Been on Flomax for a week. Have noticed that my BPH symtoms have abated somewhat. I also have PAF (parox atrial fib). Have noticed that my episodes of AF have increased. This AM was really bad, so much so that I almost blacked out on the exercise bik

Days lost to increasing incidence of atrial fibrillation, tachycardia, with ensuing weakness.

Did not fix my atrial flutter. Was put on double dose of Cardizem until ablation on friday. Hope it works!!

Fixed my atrial flutter, but know have rheumatoid arthritis, and a bad cough now for 12 weeks

Hello, I am suffering of coronary insufficiency and atrial fibrilation.I had a myocardial infarction before 6 years.Itake amiodarone and atenolol.Can i use pradaxa??

I am 57 and post valve replacement surgery/the atrial fib returned 7 months post surgery so had to go back on warfarin.I am also post menapause and have osteoporsis.My main complaint with having to take warfarin is the diet restrictions and drug inte

Atrial Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Outcome of Atrial Fibrillation Ablation After Permanent Pulmonary Vein Antrum Isolation With or Without Proven Left Atrial Posterior Wall Isolation
Condition: Atrial Fibrillation
Interventions: Procedure: Pulmonary vein antrum isolation (PVAI);   Procedure: PVAI plus left Atrial posterior wall (LAPW) isolation
Outcome Measures: Outcome of Atrial fibrillation ablation after permanent pulmonary vein antrum isolation or proven pulmonary vein antrum plus left Atrial posterior wall isolation;   Long-term outcome of Atrial fibrillation ablation after permanent pulmonary vein antrum isolation or proven pulmonary vein antrum plus left Atrial posterior wall isolation;   Quality of life after Atrial fibrillation ablation
2 Recruiting Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation
Conditions: Atrial Flutter;   Atrial Fibrillation
Interventions: Procedure: Atrial flutter ablation;   Procedure: Atrial flutter ablation and pulmonary vein isolation
Outcome Measures: Recurrence of symptomatic or asymptomatic AF as documented on an ECG or a long term Holter;   Recurrence rate of typical Atrial flutter;   Rate of occurrence of atypical flutter;   Rate of occurrence of Atrial tachycardia;   Rate of complications related to the ablation procedure;   Rate of major cardiovascular events;   All mortality rate
3 Recruiting Ablation and Left Atrium Reduction During Mitral Valve Surgery for Atrial Fibrillation
Condition: Atrial Fibrillation
Interventions: Procedure: maze procedure;   Procedure: mitral valve surgery;   Procedure: left Atrial reduction
Outcome Measures: Freedom from Atrial fibrillation;   Rate of significant adverse events
4 Recruiting Therapy of Atrial Flutter by Afib Ablation
Conditions: Atrial Fibrillation;   Atrial Flutter
Interventions: Drug: Antiarrhythmic drug;   Procedure: Cavo-tricuspid-isthmus-ablation;   Procedure: Pulmonary vein isolation
Outcome Measures: Number or patients with a recurrence of any Atrial arrhythmia;   Number of patients with Atrial flutter recurrence
5 Recruiting Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)
Condition: Paroxysmal Atrial Fibrillation
Interventions: Procedure: PVI Ablation;   Procedure: FIRM Ablation
Outcome Measures: Acute Ablation Success for Paroxysmal Atrial Fibrillation;   Long Term Ablation Success for Paroxysmal Atrial Fibrillation
6 Recruiting Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter
Condition: Atrial Fibrillation
Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Outcome Measures: The percentage of subjects with complete resolution of left Atrial or left Atrial appendage thrombus at the end of treatment;   Categories of thrombus outcome in subjects: resolved, reduced, unchanged, enlarged or new;   The composite number of stroke and non-central nervous system systemic embolism events;   The number of all bleeding events
7 Unknown  Atrial Fibrillation Ablation The Hybrid Approach Versus Traditional Management
Condition: Ablation of Atrial Fibrillation
Interventions: Procedure: Pulmonary vein isolation ablation procedure for Atrial fibrillation;   Procedure: Hybrid procedure for ablation of Atrial fibrillation;   Procedure: The Cox Maze Procedure for Ablation of Atrial Fibrillation;   Procedure: Hybrid Procedure for Left Atrium >5 cm but < 6.1 cm
Outcome Measures: Return to sinus rhythm rate;   Post procedure morbidities
8 Recruiting Atrial Fibrillation Progression Trial
Condition: Atrial Fibrillation
Interventions: Device: Left Atrial Ablation (Carto® 3, Carto® XP System, or Carto® RMT and ThermoCool®);   Drug: Rate or Rhythm Control Therapy
Outcome Measures: Time to persistent Atrial fibrillation/Atrial tachycardia excluding isthmus-dependent Atrial flutter;   Rate and time to persistent AF/AT;   Rate of persistent AF/AT by number of ablations;   Number of repeat ablations and new antiarrhythmic drugs;   Rhythm (% subjects in Sinus Rhythm, % subjects with recurrent Atrial fibrillation);   Subject's pre-existing or new onset/worsened condition(s), that may be associated with progression of Atrial fibrillation;   Catheter-related complications (ablation); adverse drug reactions (AAD);   Health care utilization (number and length of hospitalizations and unscheduled cardiovascular-related visits);   Quality of Life
9 Recruiting Assessment of Atrial Tissue Obtained From Patients Undergoing Heart Surgery and Tissue Banking
Condition: Atrial Fibrillation
Intervention: Other: Atrial tissue
Outcome Measures: Evidence of Atrial physiology;   Evidence of underlying molecular mechanisms of Atrial disease
10 Recruiting FIRM as a Stand-alone Procedure in the Treatment of Atrial Fibrillation
Condition: Atrial Fibrillation
Intervention: Procedure: FIRM ablation
Outcome Measures: Single procedure freedom from Atrial fibrillation (AF) at 12 months.;   Single procedure freedom from Atrial fibrillation (AF) at 24 months.;   Single procedure freedom from Atrial fibrillation (AF) at 30 months.
11 Recruiting Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial Fibrillation
Condition: Atrial Fibrillation
Interventions: Drug: Pradaxa;   Procedure: TEE;   Other: Compare TEE guided cardioversion to Dabigatran + DC cardioversion
Outcome Measures: Difference in function and size of the left atrium, prior to and post cardioversion comparing early cardioversion to conventional treatment group. The data for comparison will be acquired echocardiographically;   Difference in time to recurrence of, ECG or Holter verified AF, when comparing early cardioversion to conventional treatment.;   Difference in levels of inflammatory (IL-6 & CRP) and neurohumoral markers (ANP & BNP) prior to and post cardioversion, when comparing early cardioversion to conventional treatment group.;   Difference in correlation between left Atrial size and function and neurohumoral or inflammatory biomarker levels pre/post cardioversion, when comparing early cardioversion to conventional treatment group.
12 Recruiting Left Atrial Appendage Occlusion vs. Usual Care in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease
Conditions: Blood Coagulation Disorders;   Atrial Fibrillation;   Thrombosis of Left Atrial Appendage;   Chronic Kidney Disease Stage 4;   Chronic Kidney Disease Stage 5
Intervention: Device: Left Atrial appendage occlusion
Outcome Measures: Frequency of occurrence of moderate and major bleedings (Type 2 to Type 5 according to the Bleeding Academic Research Consortium (BARC) definitions);   Frequency of at least one occurrence of a combined endpoint of moderate or major bleeding and/or severe cardiovascular adverse events (stroke, cardiac infarction, thrombosis, death)
13 Recruiting Left Atrial Appendage Occlusion Study III
Conditions: Cardiac Surgery With Cardiopulmonary Bypass;   Atrial Fibrillation
Intervention: Other: Left Atrial Appendage Occlusion
Outcome Measures: Stroke or systemic arterial embolism;   Total mortality;   Operative safety outcomes;   Readmission for heart failure;   Major bleed
14 Recruiting Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Conditions: Atrial Fibrillation;   Arrhythmia
Interventions: Device: Left Atrial ablation;   Drug: Rate or Rhythm Control Therapy
Outcome Measures: LA catheter ablation is superior to rate or rhythm control drug therapy for decreasing the incidence of the composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest in patients warranting therapy for AF.;   LA catheter ablation is superior to rate or rhythm control drug therapy for reducing total mortality;   Total mortality or cardiovascular hospitalization;   Cardiovascular death;   Cardiovascular death or disabling stroke;   Arrhythmic death or cardiac arrest;   Heart failure death;   Freedom from recurrent AF;   Cardiovascular hospitalization;   Medical costs, resource utilization, and cost effectiveness;   Quality of Life;   Composite adverse events;   Left Atrial size, morphology and function and its relationship to morbidity and mortality
15 Recruiting Markers of Paroxysmal Atrial Fibrillation in Esophageal Holter Electrocardiography
Conditions: Atrial Fibrillation;   Atrial Premature Complexes
Outcome Measures: Number Atrial premature beats not conducted to the ventricles;   Mean duration of the p-eso-wave;   Mean duration of the left Atrial wavefront;   p-eso-wave-duration-dispersion;   mean number of p-eso-wave-peaks;   root mean square voltages of the last 20 ms of the p-eso-wave in the esophageal ECG
16 Recruiting Thermocool SF Catheter Versus Thermocool Catheter in Isthmus-dependent Atrial Flutter Ablation
Condition: Atrial Flutter
Interventions: Device: Atrial flutter irrigated catheter;   Device: Atrial flutter porous tip catheter
Outcome Measures: Time needed to block cavo-tricuspidal isthmus;   Radiofrequency time.;   Fluoroscopy time.;   Complications during the procedure.;   Survival free from flutter
17 Unknown  Ablating Atrial Tachycardias Occuring During Ablation of Complex Fractionated Electrograms in Persistent AF
Conditions: Atrial Fibrillation;   Ablation;   Atrial Flutter
Interventions: Procedure: Ablation;   Procedure: Cardioversion
Outcome Measures: Freedom from Atrial tachyarrhythmia;   Procedural and safety data
18 Recruiting Reduction of Fluoroscopy Exposure During Atrial Fibrillation Ablation
Condition: Atrial Fibrillation
Intervention: Device: Radio-frequency catheter ablation
Outcome Measures: Fluoroscopy time for each step of Atrial fibrillation ablation procedure;   Fluoroscopy doses for each step of Atrial fibrillation ablation procedure;   Number of patients with adverse events as a measure of safety;   Number of patients with a failure of reaching endpoints of procedure as a measure of efficacy;   Total time of Atrial fibrillation ablation procedure as a measure of efficacy
19 Recruiting Feasibility and Safety Study of LAmbre Left Atrial Appendage Occluder
Conditions: Atrial Fibrillation;   Stroke
Intervention: Device: LAmbre Left Atrial Appendage(LAA) Occluder
Outcome Measures: The feasibility end-point;   The composite safety and efficacy end-point
20 Recruiting CatHeter Ablation of perSistEnd Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation. The CHASE-AF Study
Conditions: Atrial Fibrillation;   Catheter Ablation;   Persistent Atrial Fibrillation;   Pulmonary Vein Isolation
Intervention: Procedure: Atrial fibrillation ablation
Outcome Measures: Recurrence of Atrial arrhythmia during 12 months follow up;   Number of periprocedural complications